Vitiligo-like Lesions and COVID-19: Case Report and Review of Vaccination- and Infection-Associated Vitiligo

Macca, Laura; Peterle, Lucia; Ceccarelli, Manuela; Ingrasciotta, Ylenia; Nunnari, Giuseppe; Guarneri, Claudio

doi:10.3390/vaccines10101647

Cited by 7 publications

(6 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, they found that the mean age of COVID-19 patients with vitiligo was significantly lower than those without vitiligo [ 19 ]. This finding is consistent with other studies that have reported a higher prevalence of COVID-19 in younger patients with vitiligo [ 20 ]. The duration of vitiligo appearance is also an important factor that has been studied in relation to COVID-19.…”

Section: Discussionsupporting

confidence: 93%

Post-COVID pigment loss: the connection between vitiligo and the pandemic

Dhaiban,

Abduljabbar Alfadagh,

Jasim

2024

pdia

View full text Add to dashboard Cite

Introduction Vitiligo is an acquired disorder characterized by the progressive loss of functional melanocytes, resulting in depigmented macules and patches on the skin. It affects a significant portion of the world’s population, with no specific gender or geographic predilection. Aim To explore the current understanding of the association between vitiligo and COVID-19. Material and methods This is a cross-sectional comparative research of 90 vitiligo patients, separated into two groups: those with COVID-19 confirmed by PCR and those without, gathered in 2018 before the pandemic. Al-Sadar teaching hospital in Al Basra gathered data from March 2021 to May 2022. Vitiligo patients with other infections were excluded. Wood’s test was used to confirm vitiligo (VASI score). Age, gender, site of vitiligo, number of lesions, and family history were gathered for all patients in both groups. Results Patients with vitiligo and COVID-19 had mild (70.27%), moderate (18.92%), and severe (10.81%) infections. Significant differences were found in age, duration, and VASI score, with younger patients and lower VASI scores in the Vitiligo + COVID-19 group. Females (60.6%) were more affected, and lower limbs (66.7%) were the most common site of vitiligo lesions in COVID-19 patients. Conclusions 70.27% of vitiligo and COVID-19 patients had mild infections, 18.92% had moderate infections, and 10.81% had severe infections. Patients with both disorders were younger, had shorter vitiligo durations, and lower VASI scores than those with just one. Females were more likely to have both disorders, and lower limb vitiligo was more prevalent. Family history did not affect either group.

show abstract

Section: Discussionsupporting

confidence: 93%

Post-COVID pigment loss: the connection between vitiligo and the pandemic

Dhaiban,

Abduljabbar Alfadagh,

Jasim

2024

pdia

View full text Add to dashboard Cite

show abstract

“…Laura Macca et al reviewed 16 cases of vitiligo after COVID‐19 infection and COVID‐19 vaccination reported in the literature. They realized that the symptoms of vitiligo usually appear within 1 week after vaccine administration 6 . Our patient had received the COVID‐19 vaccine 6 and 4 months before the initiation of vitiligo and the depigmented lesions appeared on the second day of receiving RDV during SARS‐CoV‐2 infection, therefore, it can be said that vaccine is unlikely to have caused the disease.…”

Section: Discussionmentioning

confidence: 81%

“…Vitiligo is an autoimmune skin disease affecting approximately 0.5%–2% of the world population and can be accompanied by other autoimmune diseases 6,7 . It is a multifactorial disorder comprising genetics and environmental factors.…”

Section: Discussionmentioning

confidence: 99%

“…Vitiligo is an autoimmune skin disease affecting approximately 0.5%–2% of the world population and can be accompanied by other autoimmune diseases. 6 , 7 It is a multifactorial disorder comprising genetics and environmental factors. The exact pathogenesis of vitiligo is not entirely understood, but immune cells and their chemokines have an important role in the etiology of the disease.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Presentation of vitiligo in a case of COVID‐19 infection concomitant with receiving remdesivir

Beyki,

Hasanzadeh,

Ghalamkarpour

2024

Clinical Case Reports

View full text Add to dashboard Cite

show abstract

“…Innate and adaptive immune responses are involved in the pathogenesis of vitiligo, with T cell subsets playing a central role, cytotoxic CD8+ T cells mediating melanocyte clearance, regulatory T cells (Treg) maintaining immune homeostasis and suppressing infammation, and skin-resident memory T cells (TRM) inducing vitiligo recurrence. Keratinocytes exacerbate the disease by secreting chemokines to recruit more cytotoxic CD8+ T cells [13,14].…”

Section: Discussionmentioning

confidence: 99%

A Retrospective Statistical Analysis of Vitiligo Exacerbation after COVID‐19 Vaccination in China

Wang,

Zhang

et al. 2023

Dermatologic Therapy

View full text Add to dashboard Cite

At present, COVID-19 vaccination is an effective method to stop the spread of the epidemic and reduce disease severity and mortality. It has been reported that COVID-19 vaccine can activate several autoimmune diseases. However, whether it can affect development of vitiligo remains elusive. In this study, we aimed to evaluate the possible risk factors of vitiligo disease activity or recurrence after COVID-19 vaccination. We recruited 383 vitiligo patients, of whom 126 were not vaccinated and 257 had received the COVID-19 vaccine. Vitiligo disease activity (VIDA) score was used to analyze key risk factors of vitiligo in patients who underwent COVID-19 vaccination. Multivariate logistic regression models were used to explore the risk factors associated with VIDA. Compared with patients without history of undergoing vaccination, the VIDA score of vaccinated patients increased significantly (3(2, 4) vs. 3(2, 3) scores, P < 0.01 ). Logistic regression analysis identified COVID-19 vaccination (odds ratio (OR): 3.040, 95% confidence interval (CI): 1.649–5.603) as an independent risk factor for VIDA. The data showed that COVID-19 vaccination aggravated the development of vitiligo, which is a key risk factor for recurrence.

show abstract

Vitiligo-like Lesions and COVID-19: Case Report and Review of Vaccination- and Infection-Associated Vitiligo

Cited by 7 publications

References 39 publications

Post-COVID pigment loss: the connection between vitiligo and the pandemic

Post-COVID pigment loss: the connection between vitiligo and the pandemic

Presentation of vitiligo in a case of COVID‐19 infection concomitant with receiving remdesivir

A Retrospective Statistical Analysis of Vitiligo Exacerbation after COVID‐19 Vaccination in China

Contact Info

Product

Resources

About